July 1 (Reuters) - Recce Pharmaceuticals Ltd (RCE) :
- RECCE PHARMACEUTICALS REPORTS POSITIVE DATA FROM PHASE I/II URINARY TRACT INFECTION (UTI) / UROSEPSIS RAPID INFUSION TRIAL OF RECCE® 327
- RECCE PHARMACEUTICALS LTD: NO SERIOUS ADVERSE EVENTS AND CLINICALLY SIGNIFICANT CHANGES OBSERVED, REINFORCING SAFETY PROFILE OF R327
- RECCE PHARMACEUTICALS LTD: ON TRACK TO INITIATE PHASE II TRIAL OF R327 IN PATIENTS WITH URINARY TRACT INFECTIONS IN H2 2024
July 1 (Reuters) - Recce Pharmaceuticals Ltd (RCE) : RECCE...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.8¢ |
Change
0.003(0.65%) |
Mkt cap ! $112.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 39.0¢ | 38.0¢ | $4.167K | 10.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24610 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 49817 | 1 |
View Market Depth
| Last trade - 15.44pm 31/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |